Colistin Use in Patients With Reduced Kidney Function

American Journal of Kidney Diseases

Volumn 68, Issue 2, 2016, Pages 296-306

  Fiaccadori, Enrico ^a   Antonucci, Elio ^b   Morabito, Santo ^c   d'Avolio, Antonio ^d   Maggiore, Umberto ^e   Regolisti, Giuseppe ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Acute kidney injury (AKI); chronic kidney disease (CKD); colistimethate; colistin; colistin methanesulfonate; colistin pharmacokinetics; continuous renal replacement therapies (CRRTs); critical illness; dialysis; hemofiltration; kidney function; nephrotoxicity; polymyxin E; renal toxicity; therapeutic drug monitors

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CHRONIC KIDNEY DISEASE; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG MONITORING; DRUG STRUCTURE; DRUG USE; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FUNCTION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PERITONEAL DIALYSIS; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; RECOMMENDED DRUG DOSE; REVIEW; TOXICITY TESTING; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; KIDNEY; KIDNEY DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG MONITORING; HUMANS; KIDNEY; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

EID: 84965021023     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.03.421     Document Type: Review

References (75)

1. 1 Fraimow, H., Nahra, R., Resistant gram-negative infections. Crit Care Clin 29:4 (2013), 895–921.
2. 2 Dudhani, R.V., Turnidge, J.D., Coulthard, K., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54:3 (2010), 1117–1124.
3. 3 Nation, R.L., Li, J., Cars, O., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:2 (2015), 225–234.
4. 4 Boisson, M., Gregoire, N., Couet, W., et al. Colistin in critically ill patients. Minerva Anestesiol 79:2 (2013), 200–208.
5. 5 Roberts, J.A., Abdul-Aziz, M.H., Lipman, J., et al. Individualized antibiotic dosing for patients who are critically ill. Challenges and potential solutions. Lancet Infect Dis 14 (2014), 498–503.
6. 6 European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST 2016. Report No.: 6.0. http://www.eucast.org. Accessed May 2, 2016.
7. 7 Bradford, P.A., Kazmierczak, K.M., Biedenbach, D.J., et al. Correlation of β-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother 60:3 (2016), 1385–1392.
8. 8 Liu, Y., Wang, Y., Walsh, T.R., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168.
9. 9 Bassetti, M., Righi, E., New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr Opin Crit Care 21:5 (2015), 402–411.
10. 10 Giamarellos-Bourboulis, E.J., Xirouchaki, E., Giamarellou, H., et al. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40:3 (2001), 117–120.
11. 11 Gunderson, B.W., Ibrahim, K.H., Hovde, L.B., et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47:3 (2003), 905–909.
12. 12 Deris, Z.Z., Yu, H.H., Davis, K., et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56:10 (2012), 5103–5112.
13. 13 Mohamed, A.F., Karaiskos, I., Plachouras, D., et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:8 (2012), 4241–4249.
14. 14 Azak, M.A., Huang, J.X., Cooper, M.A., et al. Structure–activity relationships for the binding of polymyxins with human α-1-acid glycoprotein. Biochem Pharmacol 84 (2012), 278–291.
15. 15 Couet, W., Grégoire, N., Gobin, P., et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:6 (2011), 875–879.
16. 16 Garonzik, S.M., Li, J., Thamlikitkul, V., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:7 (2011), 3284–3294.
17. 17 Karnik, N.D., Sridharan, K., Jadhav, S.P., et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram negative bacilli infection. Eur J Clin Pharmacol 69:7 (2013), 1429–1436.
18. 18 Couet, W., Grégoire, N., Marchand, S., et al. Colistin pharmacokinetics: the fog is lifting. Clin Microbol Infect Dis 18:1 (2012), 30–39.
19. 19 Plachouras, D., Karvanen, M., Friberg, L.E., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:8 (2009), 3430–3436.
20. 20 Imberti, R., Cusato, M., Villani, P., et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:6 (2010), 1333–1339.
21. 21 Athanassa, Z.E., Markantonis, S.L., Fousteri, M.Z., et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38:11 (2012), 1779–1786.
22. 22 Tumbarello, M., De Pascale, G., Trecarichi, E.M., et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144:6 (2013), 1768–1775.
23. 23 Valachis, A., Samonis, G., Kofteridis, D.P., The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 43:3 (2015), 527–533.
24. 24 Dalfino, L., Puntillo, F., Ondok, M.J., et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis 61:12 (2015), 1771–1777.
25. 25 Liu, D., Zhang, J., Liu, H.X., Zhu, Y.G., Qu, J.M., Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis. Int J Antimicrob Agents 46:6 (2015), 603–609.
26. 26 Michalopulos, A.S., Falagas, M.E., Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 1:1 (2011), 30–35.
27. 27 Owen, R.J., Li, J., Nation, R.L., et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59:3 (2007), 473–477.
28. 28 Honoré, P.M., Jacobs, R., Joannes-Boyau, O., et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 37:4 (2014), 291–295.
29. 29 Falagas, M.E., Kasiakou, S.K., Kofteridis, D.P., et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram negative bacteria. Clin Microbiol Infect 12:12 (2006), 1227–1230.
30. 30 Spapen, H.D., Honore, P.M., Gregoire, N., et al. Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin. J Infect 63:6 (2011), 468–470.
31. 31 Honorè, P.M., Jacobs, R., Lochy, S., et al. Acute respiratory weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis 6 (2013), 107–111.
32. 32 Collins, J.M., Haynes, K., Gallagher, J.C., et al. Emergent renal dysfunction with colistin. Pharmacotherapy 33:8 (2013), 812–816.
33. 33 Sorlí, L., Luque, S., Grau, S., et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13 (2013), 380–390.
34. 34 Deryke, C.A., Crawford, A.J., Uddin, N., et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54:10 (2010), 4503–4505.
35. 35 Rocco, M., Montini, L., Alessandri, E., et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17:4 (2013), R174–R184.
36. 36 Phe, K., Lee, Y., McDaneld, P.M., et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:5 (2014), 2740–2746.
37. 37 Trifi, A., Abdellatif, S., Daly, F., et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy 61:4 (2016), 190–196.
38. 38 Javan, A.O., Shokouhi, S., Sahraei, Z., A review on colistin nephrotoxicity. Eur J Pharmacol 71 (2015), 801–810.
39. 39 Gauthier, T.P., Wolowich, W.R., Reddy, A., et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 56:5 (2012), 2392–2396.
40. 40 Tuon, F.F., Rigatto, M.H., Lopes, C.K., et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43:4 (2014), 349–352.
41. 41 Rigatto, M.H., Behle, T.F., Falci, D.R., et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70:5 (2015), 1552–1557.
42. 42 Pogue, J.M., Lee, J., Marchaim, D., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:9 (2011), 879–884.
43. 43 Lee, Y.J., Wi, Y.M., Kwon, Y.J., Kim, S.R., Chang, S.H., Cho, S., Association between colistin dose and development of nephrotoxicity. Crit Care Med 43:6 (2015), 1187–1193.
44. 44 Nilsson, A., Goodwin, R.J., Swales, J.G., et al. Investigating nephrotoxicity of polymyxin derivatives by mapping renal distribution using mass spectrometry imaging. Chem Res Toxicol 28:9 (2015), 1823–1830.
45. 45 Yun, B., Azad, M.A., Wang, J., et al. Imaging the distribution of polymyxins in the kidney. J Antimicrob Chemother 70:3 (2015), 827–829.
46. 46 Suzuki, T., Yamaguchi, H., Ogura, J., et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 57:12 (2013), 6319–6324.
47. 47 Dai, C., Li, J., Tang, S., et al. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 58:7 (2014), 4075–4085.
48. 48 Dai C, Tang S, Velkov T, Xiao X. Colistin-induced apoptosis of neuroblastoma-2a cells involves the generation of reactive oxygen species, mitochondrial dysfunction, and autophagy [published online ahead of print August 28, 2015]. Mol Neurobiol. http://dx.doi.org/10.1007/s12035-015-9396-7.
49. 49 Ozkan, G., Ulusoy, S., Orem, A., et al. How does colistin-induced nephropathy develop and can it be treated?. Antimicrob Agents Chemother 57:8 (2013), 3463–3469.
50. 50 Azad, M.A., Akter, J., Rogers, K.L., Nation, R.L., Velkov, T., Li, J., Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother 59:4 (2015), 2136–2143.
51. 51 Dai, C., Tang, S., Deng, S., et al. Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway. Antimicrob Agents Chemother 59:1 (2015), 579–585.
52. 52 Yousef, J.M., Chen, G., Hill, P.A., et al. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67:2 (2012), 452–459.
53. 53 Sirijatuphat, R., Limmahakhun, S., Sirivatanauksorn, V., Nation, R.L., Li, J., Thamlikitkul, V., Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 59:6 (2015), 3224–3232.
54. 54 Brown, J.M., Dorman, D.C., Roy, L.P., et al. Acute renal failure due to overdosage of colistin. Med J Aust 2:20 (1970), 923–924.
55. 55 Rao, G.G., Ly, N.S., Haas, C.E., et al. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 58:3 (2014), 1381–1388.
56. 56 Kift, E.V., Maartens, G., Bamford, C., Systematic review of the evidence for rational dosing of colistin. S Afr Med J 104:3 (2014), 183–186.
57. 57 John, E., Bennett, R.D., Blaser, M.J., Polymyxins (polymyxin B and colistin). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th ed., 2015, Elsevier Saunders, Philadelphia, PA, 549–555.
58. 58 Koomanachai, P., Landersdorfer, C.B., Chen, G., et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 58:1 (2014), 440–446.
59. 59 The Sanford Guide to Antimicrobial Therapy Mobile App. 2016 digital edition. Accessed March 2, 2016.
60. 60 Li, J., Rayner, C.R., Nation, R.L., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:11 (2005), 4814–4815.
61. 61 Markou, N., Fousteri, M., Markantonis, S.L., et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 67:10 (2012), 2459–2462.
62. 62 Karvanen, M., Plachouras, D., Friberg, L.E., et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 57:1 (2013), 668–671.
63. 63 Akers, K.S., Rowan, M.P., Niece, K.L., et al. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration. Antimicrob Agents Chemother 59:1 (2015), 46–52.
64. 64 Leporati, M., Bua, R.O., Mariano, F., et al. Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 36:2 (2014), 182–191.
65. 65 Mariano, F., Leporati, M., Carignano, P., et al. Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol 28:5 (2014), 623–631.
66. 66 Marchand, S., Frat, J.P., Petitpas, F., et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:8 (2010), 1836–1837.
67. 67 Jacobs, M., Gregoire, N., Megarbane, B., et al. Population pharmacokinetics of colistin methanesulphonate 1 (CMS) and colistin in 2 critically ill patients with acute renal failure requiring intermittent hemodialysis. Antimicrob Agents Chemother 60:3 (2016), 1788–1793.
68. 68 Strunk, A.K., Schmidt, J.J., Baroke, E., et al. Single- and multiple dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. J Antimicrob Chemother 69:7 (2014), 2008–2010.
69. 69 Jitmuang, A., Nation, R.L., Koomanachai, P., et al. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother 70:6 (2015), 1804–1811.
70. 70 Thomas, T.A., Broun, E.C., Abildskov, K.M., et al. High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 34:4 (2012), 398–405.
71. 71 Cheng, C., Liu, S., Xiao, D., Hollembaek, J., et al. LC-MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 878:28 (2010), 2831–2838.
72. 72 Ma, Z., Wang, J., Gerber, J.P., Milne, R.W., Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 862 (2008), 205–212.
73. 73 Dijkmans, A.C., Wilms, E.B., Kamerling, I.M., et al. Colistin: revival of an old polyymyxin antibiotic. Ther Drug Monit 37 (2015), 419–427.
74. 74 Bode-Böger, S.M., Schopp, B., Tröger, U., Martens-Lobenhoffer, J., Kalousis, K., Mailänder, P., Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int J Antimicrob Agents 42 (2013), 357–360.
75. 75 Nation, R.L., Garonzik, S.M., Thamlikitkul, V., et al. Updated US and European dose recommedations for intravenous colistin: how do they perform?. Clin Infect Dis 62:5 (2016), 552–558.